Slide 1: Evolving stronger, growing together
Evolving stronger, growing together Analyst presentation 2025 first nine months trading update 6 November 2025
Slide 2: Presenting team
Presenting team Marcus Jordan Hans Kooijmans CEO CFO 2
Slide 3: Agenda
1 Highlights Q3 2025 2 Financials Q3 2025 3 Outlook 4 Q&A 5 Annex 3
Slide 4: Highlights 2025 first nine months
Highlights 2025 first nine months Gross profit Operating EBITA Free cash flow Cash earnings per share EUR 927 million EUR 394 million EUR 284 million EUR 4.16 +5% on a constant +1% on a constant Q3 2024: EUR 299 Q3 2024: EUR 4.67 currency basis currency basis million 4
Slide 5: Highlights 2025 first nine months: M&A
Highlights 2025 first nine months: M&A ● Tecom (Spain) – Food and nutrition (signed May 2025, closed July 2025) EMEA ● Ferrer (Spain) – Food and nutrition (signed and closed June 2025) ● Tillmans (Italy) – Coatings & construction, food & nutrition, water treatment (signed August 2025, closing expect
Slide 6: Financials Q3 2025
Highlights Financials Outlook Q&A Annex Q3 2025 Q3 2025
Slide 7: Financials Q3 2025 – key figures
Financials Q3 2025 – key figures Jan. 1 - Sep. Jan. 1 - Sep. Fx. adj. EUR million 30, 2025 30, 2024 Change Change % change Revenue 3,676 3,584 92 3% 6% Gross profit 927 909 18 2% 5% Gross profit as a % of revenue 25.2% 25.4% (0.2%) Operating EBITA 394 403 (9) (2%) 1% Operating EBITA as a % of revenu
Slide 8: Financials Q3 2025 – segment information
Financials Q3 2025 – segment information Asia- Holding EUR million EMEA Americas Pacific companies Total Gross profit YTD Q3 2025 434 276 217 927 YTD Q3 2024 422 273 214 909 organic growth 2% 0% 1% 1% acquisition growth 2% 6% 5% 4% currency impact (1%) (5%) (4%) (3%) Operating EBITA YTD Q3 2025 181
Slide 9: Financials Q3 2025 – Free cash flow
Financials Q3 2025 – Free cash flow Jan. 1 - Jan. 1 - Sep. 30, Sep. 30, EUR million 2025 2024 Change Operating EBITA 394 403 (9) Depreciation 31 31 - Operating EBITDA 425 434 (9) Lease payments (25) (24) (1) Share based payments 3 3 - Adjusted operating EBITDA 403 413 (10) Capex (9) (7) (2) ∆ Workin
Slide 10: Financials Q3 2025 – net debt
Financials Q3 2025 – net debt 30 September 31 December 30 September EUR million 2025 2024 2024 Reported net debt: 1,510 1,282 1,585 Reported leverage ratio: Reported (incl. full year impact of acquisitions) 2.6 2.2 2.8 Leverage ratio based on loan documentation: Actual based on loan documentation 2.
Slide 11: Outlook
Highlights Financials Outlook Q&A Annex Q3 2025 Q3 2025
Slide 12: Outlook
Outlook IMCD operates in different, often fragmented market segments in multiple geographic regions, connecting many customers and suppliers across a very diverse product range. In general, results are impacted by macroeconomic conditions and developments in specific industries. Results can be influ
Slide 13: Q&A
Highlights Financials Outlook Q&A Annex Q3 2025 Q3 2025
Slide 14: Annex
Highlights Financials Outlook Q&A Annex Q3 2025 Q3 2025
Slide 15: We are IMCD
We are IMCD IMCD is a leading global partner for the distribution and formulation of speciality chemicals and ingredients. ● Adaptable business model driving simplification for our partners ● Formulatory and solutions provider ● Comprehensive and complementary speciality portfolio ● Global footprint
Slide 16: Business Groups focusing on strategic market segments
8 Business Groups focusing on strategic market segments Pharmaceuticals Coatings & Construction Food & Nutrition Advanced Materials Excipients; APIs; Coatings; decorative paints; Dairy; savoury; bakery; Compounders; converters; nutraceuticals; synthesis; adhesives & sealants; textile & beverage; ani
Slide 17: High scores on external ESG ratings
High scores on external ESG ratings Demonstrating our continuous focus on best practices Score B (2024) Platinum (2025) Score B (2023) Gold (2024) On a scale of A to D- ESG Risk Rating 11.6, low risk (2025) B- (Prime) rating 12.6 (2024) C+ rating (2024) On a scale of A+ to D- 17
Slide 18: Disclaimer
Disclaimer This presentation may contain forward looking statements. These statements are based on current expectations, estimates and projections of IMCD’s management and information currently available to the company. IMCD cautions that such statements contain elements of risk and uncertainties th